BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders

Core Viewpoint - BioSig Technologies, Inc. is focused on enhancing shareholder value through new management initiatives and operational improvements, particularly in its PURE EP™ Biomedical Signal Processing Technology [1][4]. Group 1: Management and Governance - The newly assembled Board of Directors includes five experienced individuals, with three serving as independent directors, and all committees have been fully constituted [3]. - A revamped Business Advisory Board is being formed to explore business opportunities and potential mergers and acquisitions [3]. Group 2: Operational Focus - Despite recent leadership changes, the company remains committed to its core business and continues to maintain partnerships with major institutions in the electrophysiology sector [4]. - The company is actively working to demonstrate the value of its PURE EP platform to stakeholders and shareholders [4]. Group 3: Technology and Innovation - BioSig sees significant opportunities in the AI sector, particularly in generative data compilation and commercialization through proprietary algorithms for interventional cardiology [5]. - The PURE EP™ Platform is an FDA 510(k) cleared non-invasive class II device that enhances real-time signal visualization for cardiac ablation procedures [8]. Group 4: Compliance and Financial Health - The company presented to the Nasdaq Hearings Panel and has regained compliance with the minimum bid price requirement [6]. - Ongoing updates will be provided to shareholders regarding compliance issues following the hearing [6].